[2][3][4] Leen Kawas served as the company's first President and CEO,[5] but resigned in October 2021,[6] after an independent special committee found she "altered images in scientific papers she authored.

"[7] In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant.

[7] The company has received financial support from venture capitalist groups and angel investors through four rounds of funding to date.

[10][11] The company's lead asset, ATH-1017, is in human trials of Alzheimer's disease as of 2021.

[12] ATH-1017 is a small molecule therapeutic specifically designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, which are expressed in normal central nervous system function.